



# 30th ESTS MEETING

19 - 21 JUNE 2022 • THE HAGUE, THE NETHERLANDS



## LUNCH SYMPOSIA

AstraZeneca 

Monday 20, June

12:30-13:30

Room: Yangtze 1&2

### OPTIMISING OUTCOMES FOR PATIENTS WITH RESECTABLE EGFRM NSCLC

#### Objectives

- To review recent developments in (neo)adjuvant treatment options for patients with resectable NSCLC and examine how these may influence clinical decision making
- To discuss how biomarker testing is evolving in early-stage NSCLC and how this, alongside advancements in staging, can improve patient identification and selection for targeted therapies
- To discuss reducing the risk of CNS progression in resectable EGFRm NSCLC by considering the optimal diagnostic pathway and post-surgical treatment considerations

- 
- Introduction to the faculty and overview of the meeting agenda  
Walter Weder (Zurich / CH)
  - Advances in (neo)adjuvant therapy and optimal patient identification  
Ugo Pastorino (Milan / IT)
  - Optimizing patient outcomes in resectable EGFRm NSCLC  
Karen Harrison-Phipps (London / UK)
  - CNS progression following surgery in EGFRm NSCLC patients - minimizing the risk and optimizing management  
Margarita Majem (Barcelona / ES)
  - Live Q&A and panel discussion: Emerging landscape in personalized (neo) adjuvant therapy  
All faculty & audience
  - Meeting close  
Walter Weder (Zurich / CH)



# 30th ESTS MEETING

19 - 21 JUNE 2022 • THE HAGUE, THE NETHERLANDS



## LUNCH SYMPOSIA

**Medtronic**

Moderator: Didier Schneiter (Zurich/CH)

### THE BENEFITS OF SIMULATION TRAINING

Professor Rene Petersen (Copenhagen/DK)

Dr Kelvin Lau (London/UK)

Dr Sri Subramaniam (Oxford/UK)

Monday 20, June

12:30-13:30

Room: Amazon

### INSIGHTS AND EXPERIENCES OF ELECTROMAGNETIC NAVIGATIONAL BRONCHOSCOPY TECHNOLOGY

Dr Kelvin Lau (London/UK)



# 30th ESTS MEETING

19 - 21 JUNE 2022 • THE HAGUE, THE NETHERLANDS



## LUNCH SYMPOSIA



Monday 20, June  
12:30-13:30  
Room: Onyx

### **SURGERY AND IMMUNO-ONCOLOGY – THE NEW FRONTIER IN EARLY-STAGE NSCLC**

- Welcome and opening remarks  
Giulia Veronesi (Milan/IT)
- Current treatment modalities used in earlystage NSCLC: Focus on different surgical approaches and adjuvant treatments  
Paul Van Schil (Antwerp/BE)  
Solange Peters (Lausanne/CH)
- Developments in systemic treatment modalities for early-stage NSCLC  
Solange Peters (Lausanne/CH)
- Role of biomarkers in defining treatment of early-stage LC patients  
Keith Kerr (Aberdeen/UK)
- Early-stage NSCLC patient management based on case studies (adjuvant setting)  
Giulia Veronesi (Milan/IT)
- Live Q&A  
All
- Closing remarks  
Giulia Veronesi (Milan /IT)